Prieto 1994.

Methods	Setting: Spain, hospital outpatient clinic Randomised: yes, computer‐generated randomisation schedule. Allocation concealment: not employed Design: parallel Intervention period: 4 months Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=3
Participants	30 adults, 28 completed: 8M 20F Mean (SD) age: budesonide 33(3) years, placebo 35 (2) years Inclusion criteria: Patients with seasonal asthma for at least 2 years FEV1 (% predicted) > 80 Positive skin prick test to grass or other pollens but not to other allergens such as house dust mite, cat or dog Exclusion criteria: Inhaled corticosteroid use Serious coexistent disease Chest infection within last 4 weeks
Interventions	BUD: 400 mcg 1 pf 2xdaily (800mcg/d) Placebo: 1 pf 2xdaily Delivery device: MDI+spacer
Outcomes	FEV1 Methacholine BHR (PC20 FEV1)
Notes	Reply from author clarifying method of random order generation and that allocation concealment was not employed. Study was undertaken during the period of maximum allergen exposure (March to June).
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used